ReFacto AF


moroctocog alfa

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR) for ReFacto AF. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for ReFacto AF.

This EPAR was last updated on 08/11/2022

Authorisation details

Product details
ReFacto AF
Agency product number
Active substance
moroctocog alfa
International non-proprietary name (INN) or common name
moroctocog alfa
Therapeutic area (MeSH)
Hemophilia A
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Pfizer Europe MA EEIG
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Boulevard de la Plaine 17
1050 Bruxelles

Product information

08/11/2022 ReFacto AF - EMEA/H/C/000232 - N/0166

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group


Therapeutic indication

Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor-VIII deficiency).

ReFacto AF is appropriate for use in adults and children of all ages, including newborns.

ReFacto AF does not contain von-Willebrand factor, and hence is not indicated in von-Willebrand's disease.

Assessment history

Changes since initial authorisation of medicine

Related content

How useful was this page?

Add your rating
2 ratings
1 rating